AmyriAD Therapeutics

CompanyUnited States

AmyriAD Therapeutics develops one asset, in human trials (Inidascamine in cognitive impairment associated with schizophrenia). Mostly small molecule; based in the United States.

1
Asset
Furthest stage
Human trials
0
Trials
1
Signal

Pipeline

1
  • Inidascamine

    Human trials, Small molecule, cognitive impairment associated with schizophrenia

Full company profiles: pipeline, trials, funding and people.

See Pro

In the full profile

  • Signals1

Intelligence